**Core Concept**
The question is testing the concept of how to manage local anesthetic toxicity in patients with hypertension. The underlying principle involves the use of a drug that can help prolong the action of local anesthetics (LAs) while minimizing the risk of systemic toxicity, particularly in patients with hypertension.

**Why the Correct Answer is Right**
The correct answer is a drug that inhibits the enzyme P-glycoprotein (P-gp) and the cytochrome P450 enzyme system, specifically CYP3A4. This inhibition leads to increased levels of the local anesthetic in the plasma, thereby prolonging its duration of action. In patients with hypertension, this is particularly useful as it allows for the administration of a smaller dose of the local anesthetic, reducing the risk of systemic toxicity. The drug in question also has a role in reducing the clearance of other drugs that are substrates for CYP3A4.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it is not directly related to the prolongation of local anesthetic action.
* **Option B:** This option is incorrect because it is not a known inhibitor of P-gp or CYP3A4.
* **Option C:** This option is incorrect because it is not a drug that is typically used to prolong the action of local anesthetics.

**Clinical Pearl / High-Yield Fact**
In patients with hypertension, it is essential to use a local anesthetic that has a low potential for systemic toxicity, such as a drug that is primarily metabolized by ester hydrolysis. Additionally, the use of a P-gp and CYP3A4 inhibitor can help prolong the duration of action of the local anesthetic, reducing the risk of systemic toxicity.

**Correct Answer: B. Midazolam **